See more : CJ Cheiljedang Corporation (097955.KS) Income Statement Analysis – Financial Results
Complete financial analysis of MedPacto, Inc. (235980.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedPacto, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Dynamic Precision Industry Corporation (8928.TWO) Income Statement Analysis – Financial Results
- Briscoe Group Limited (BGP.AX) Income Statement Analysis – Financial Results
- Veranda Learning Solutions Limited (VERANDA.NS) Income Statement Analysis – Financial Results
- Castor Maritime Inc. (CTRM) Income Statement Analysis – Financial Results
- Canadian Western Bank (CBWBF) Income Statement Analysis – Financial Results
MedPacto, Inc. (235980.KQ)
About MedPacto, Inc.
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.83B | 1.87B | 1.72B | 1.44B | 835.57M | 190.26M | 170.08M |
| Gross Profit | -1.83B | -1.87B | -1.72B | -1.44B | -835.57M | -190.26M | -170.08M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.50B | 30.31B | 23.12B | 22.81B | 9.96B | 9.43B | 2.84B |
| General & Administrative | 264.73M | 250.56M | 126.08M | 139.27M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.45B | 1.01B | 948.20M | 697.13M | 0.00 | 0.00 | 0.00 |
| SG&A | 4.42B | 5.04B | 4.61B | 3.54B | 2.44B | 542.20M | 227.16M |
| Other Expenses | 0.00 | -31.21M | -12.46M | -13.91M | -7.96M | -125.00K | -62.50K |
| Operating Expenses | 26.92B | 35.38B | 27.74B | 26.36B | 12.40B | 9.97B | 3.06B |
| Cost & Expenses | 28.75B | 37.25B | 29.46B | 27.80B | 13.24B | 10.16B | 3.23B |
| Interest Income | 388.46M | 1.32B | 663.52M | 508.79M | 439.25M | 122.80M | 1.80M |
| Interest Expense | 493.23M | 9.62B | 7.77B | 31.27M | 247.00M | 432.03M | 381.86M |
| Depreciation & Amortization | 1.83B | 1.87B | 1.72B | 1.44B | 835.57M | 190.26M | 170.08M |
| EBITDA | -32.61B | -23.74B | -7.19B | -25.64B | -12.33B | -36.70B | -2.92B |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -28.75B | -37.25B | -29.46B | -27.80B | -13.24B | -10.16B | -3.23B |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.18B | 1.97B | 12.78B | 691.66M | -177.07M | -27.16B | -234.60M |
| Income Before Tax | -34.93B | -35.23B | -16.68B | -27.11B | -13.42B | -37.32B | -3.47B |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 525.38M | 361.10M | -1.76B | 100.09M | 259.88M | 0.00 |
| Net Income | -35.32B | -35.75B | -17.04B | -25.35B | -13.52B | -37.58B | -3.47B |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.66K | -1.46K | -710.63 | -1.07K | -571.43 | -1.54K | -141.88 |
| EPS Diluted | -1.66K | -1.46K | -710.63 | -1.07K | -571.43 | -1.54K | -141.88 |
| Weighted Avg Shares Out | 21.22M | 24.56M | 23.98M | 23.77M | 23.65M | 24.45M | 24.45M |
| Weighted Avg Shares Out (Dil) | 21.22M | 24.56M | 23.98M | 23.77M | 23.65M | 24.45M | 24.45M |
Source: https://incomestatements.info
Category: Stock Reports